Rice Hall James & Associates LLC Acquires 639,024 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Rice Hall James & Associates LLC grew its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 46.6% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,010,104 shares of the biopharmaceutical company's stock after acquiring an additional 639,024 shares during the period. Rice Hall James & Associates LLC owned 0.65% of Amicus Therapeutics worth $16,402,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Virtus Fund Advisers LLC acquired a new stake in Amicus Therapeutics during the fourth quarter valued at $29,000. Covestor Ltd lifted its holdings in shares of Amicus Therapeutics by 114.9% during the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after buying an additional 2,312 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Amicus Therapeutics during the 4th quarter valued at about $59,000. GAMMA Investing LLC grew its stake in shares of Amicus Therapeutics by 1,610.8% in the 1st quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock valued at $61,000 after buying an additional 7,007 shares in the last quarter. Finally, Sciencast Management LP acquired a new position in Amicus Therapeutics in the fourth quarter worth approximately $100,000.

Amicus Therapeutics Stock Performance

FOLD traded up $0.15 during trading on Monday, hitting $6.24. The stock had a trading volume of 2,327,993 shares, compared to its average volume of 3,797,046. The firm has a market cap of $1.92 billion, a PE ratio of -69.33 and a beta of 0.51. The company has a current ratio of 3.34, a quick ratio of 2.47 and a debt-to-equity ratio of 2.02. Amicus Therapeutics, Inc. has a 12 month low of $5.51 and a 12 month high of $12.65. The company has a 50 day simple moving average of $6.07 and a 200-day simple moving average of $7.76.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on FOLD. Wall Street Zen cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. The Goldman Sachs Group reduced their price objective on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Finally, UBS Group increased their target price on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $16.22.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.